Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03772028
Active, not recruiting Phase 3

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

NCT03772028 · tracked via the Priya Life Science France tracker
Sponsor
The Netherlands Cancer Institute
Phase
Phase 3
Started
2020-01-01
Last updated
2026-04-08

Condition(s) studied

Ovarian Cancer

Investigational drug(s) / intervention(s)

cisplatin →

cisplatin: HIPEC with cisplatin after cytoreductive surgery

Study summary

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * candidate for primary CRS * histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer Exclusion Criteria: * history of previous malignancies within 5 years prior to inclusion * FIGO stage IV disease * complete primary cytoreduction is impossible * prior treatment for the current malignancy

Primary outcome measure(s)

  • overall survival — 1 year after last patient last visit

Trial sites (28)

FacilityCityRegionStatus
City of Hope Duarte California
MSKCC New York New York New York
Rigshospitalet Copenhagen Copenhagen Denmark
CHU de Besancon Besançon France
Institut Bergonié Bordeaux France
o Institut Bergonié, Bordeaux Bordeaux France
CHU Lille Lille France
Centre Leon Berard, Lyon Lyon France
CHU Lyon Lyon France
Institut du Cancer Montpellier Montpellier France
Institut de Cancerologie de l'Ouest, ICO Nantes) Nantes France
Institut Curie Paris Paris France
CHRU Strasbourg Strasbourg France
Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse) Toulouse France
Mater Misericordiae University Hospital, Dublin Dublin Ireland
Policlinico Sant'Orsola, Bologna Bologna Italy
Fondazione Policlinico A Gemelli IRCCS Roma Italy
Antoni van leeuwenhoek Amsterdam North Holland
Amsterdam UMC Amsterdam Netherlands
Catharina Hospital Eindhoven Netherlands
Medisch Spectrum Twente Enschede Netherlands
UMCG Groningen Netherlands
Leiden University Medical Center (LUMC) Leiden Netherlands
Maastricht UMC+ Maastricht Netherlands
Radboud MC Nijmegen Netherlands
Erasmus MC Rotterdam Netherlands
UMCU Utrecht Netherlands
Alice Bjoernlund-Larsen Uppsala Sweden

More The Netherlands Cancer Institute trials in France

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Active, not recruiting

Other trials for the same condition

Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal Active, not recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Starting soon
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03772028 on ClinicalTrials.gov ↗ ← All trials in France